Browse by Person

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | No Grouping
Number of items: 6.

Newell-Price, J., Pivonello, R., Tabarin, A. et al. (9 more authors) (2020) Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease. European Journal of Endocrinology, 182 (2). pp. 207-217. ISSN 0804-4643

Fleseriu, M., Petersenn, S., Biller, B.M.K. et al. (9 more authors) (2019) Long‐term efficacy and safety of once‐monthly pasireotide in Cushing's disease: A Phase III extension study. Clinical Endocrinology, 91 (6). pp. 776-785. ISSN 0300-0664

Johannsson, G., Bidlingmaier, M., Biller, B.M.K. et al. (28 more authors) (2018) Growth Hormone Research Society perspective on biomarkers of GH action in children and adults. Endocrine Connections, 7 (3). R126-R134. ISSN 2049-3614

Lacroix, A., Gu, F., Gallardo, W. et al. (12 more authors) (2017) Efficacy and safety of once-monthly pasireotide in Cushing's disease: A 12 month clinical trial. The Lancet Diabetes and Endocrinology. ISSN 2213-8587

Findling, J.W., Fleseriu, M., Newell-Price, J. et al. (5 more authors) (2016) Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing’s disease: 12-month, Phase III pasireotide study. Endocrine, 54 (2). pp. 516-523. ISSN 1355-008X

Allen, D.B., Backeljauw, P., Bidlingmaier, M. et al. (37 more authors) (2016) GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 174 (2). P1-P9. ISSN 0804-4643

This list was generated on Sun Jul 5 19:49:41 2020 BST.